Fulgent Genetics is recognized as a specialized technology-centric healthcare company providing comprehensive clinical genetic testing, oncology panels, and reproductive health screening services. The firm gained widespread prominence during public health testing surges and maintains a robust balance sheet with zero debt. While its legacy COVID-19 testing revenues normalized, its core clinical genetic testing business continues to expand, making it an intriguing option for investors tracking molecular diagnostics.